Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2

Journal of Molecular and Cellular Cardiology

Volumn 84, Issue , 2015, Pages 143-153

  Wang, Hui ^a,b   Lai, Yimu ^b   Mathis, Bryan J ^b   Wang, Wenjuan ^a,b   Li, Siying ^a,b   Qu, Chen ^a,b   Li, Bin ^a,b   Shao, Lei ^a,b   Song, Haibo ^a,b   Janicki, Joseph S ^b   Sun, Sao Cong ^c   Wang, Xing Li ^a   Tang, Dongqi ^a   Cui, Taixing ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cardiomyopathy; CYLD; Heart failure; Nrf2; Oxidative stress

Indexed keywords

CYCLINDROMATOSIS PROTEIN; DEUBIQUITINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PROTEIN C JUN; PROTEIN FOS; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CYLD PROTEIN, HUMAN; CYLD PROTEIN, MOUSE; CYLD PROTEIN, RAT; CYSTEINE PROTEINASE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CASE REPORT; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL RATE; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CARDIOMEGALY; COMPLICATION; DOWN REGULATION; ECHOGRAPHY; ENZYMOLOGY; GENE SILENCING; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PRESSURE; RAT; SIGNAL TRANSDUCTION; SURVIVAL;

MURINAE; MUS;

ANIMALS; CARDIOMEGALY; CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HEART FAILURE; HUMANS; MALE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRESSURE; PROTO-ONCOGENE PROTEINS C-MYC; RATS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION FACTOR AP-1; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84928885775     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.04.012     Document Type: Article

References (41)

1. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
2. Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009, 10:319-331.
3. Amerik A.Y., Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 2004, 1695:189-207.
4. Willis M.S., Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006, 41:567-579.
5. Cook S.A., Novikov M.S., Ahn Y., Matsui T., Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 2003, 108:664-667.
6. Li H.L., Zhuo M.L., Wang D., Wang A.B., Cai H., Sun L.H., et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 2007, 115:1885-1894.
7. Huang H., Tang Q.Z., Wang A.B., Chen M., Yan L., Liu C., et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 2010, 56:232-239.
8. Bignell G.R., Warren W., Seal S., Takahashi M., Rapley E., Barfoot R., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000, 25:160-165.
9. Sun S.C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010, 17:25-34.
10. Lim J.H., Jono H., Komatsu K., Woo C.H., Lee J., Miyata M., et al. CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun 2012, 3:771.
11. Nikolaou K., Tsagaratou A., Eftychi C., Kollias G., Mosialos G., Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012, 21:738-750.
12. Liu S., Lv J., Han L., Ichikawa T., Wang W., Li S., et al. A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 420:78-83.
13. Li J., Ichikawa T., Villacorta L., Janicki J.S., Brower G.L., Yamamoto M., et al. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009, 29:1843-1850.
14. Li J., Zhang C., Xing Y., Janicki J.S., Yamamoto M., Wang X.L., et al. Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc Res 2011, 90:315-324.
15. Li S., Wang W., Niu T., Wang H., Li B., Shao L., et al. Nrf2 deficiency exaggerates doxorubicin-induced cardiotoxicity and cardiac dysfunction. Oxid Med Cell Longev 2014, 2014:748524.
16. Wang W., Li S., Wang H., Li B., Shao L., Lai Y., et al. Nrf2 enhances myocardial clearance of toxic ubiquitinated proteins. J Mol Cell Cardiol 2014, 72:305-315.
17. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
18. Reiley W.W., Zhang M., Jin W., Losiewicz M., Donohue K.B., Norbury C.C., et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006, 7:411-417.
19. O'Connell T.D., Swigart P.M., Rodrigo M.C., Ishizaka S., Joho S., Turnbull L., et al. Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 2006, 116:1005-1015.
20. Dominguez E., Ruberte J., Rios J., Novellas R., Del Alamo M.M., Navarro M., et al. Non-invasive in vivo measurement of cardiac output in C57BL/6 mice using high frequency transthoracic ultrasound: evaluation of gender and body weight effects. Int J Cardiovasc Imaging 2014, 30:1237-1244.
21. Hikoso S., Yamaguchi O., Nakano Y., Takeda T., Omiya S., Mizote I., et al. The I{kappa}B kinase {beta}/nuclear factor {kappa}B signaling pathway protects the heart from hemodynamic stress mediated by the regulation of manganese superoxide dismutase expression. Circ Res 2009, 105:70-79.
22. Kratsios P., Huth M., Temmerman L., Salimova E., Al Banchaabouchi M., Sgoifo A., et al. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKKgamma in cardiomyocytes. Circ Res 2010, 106:133-144.
23. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
24. Zhang G.X., Lu X.M., Kimura S., Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res 2007, 76:204-212.
25. Fu Y.C., Chi C.S., Yin S.C., Hwang B., Chiu Y.T., Hsu S.L. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc Res 2004, 62:558-567.
26. Dhingra S., Sharma A.K., Singla D.K., Singal P.K. p38 and ERK1/2 MAPKs mediate the interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2007, 293:H3524-H3531.
27. Zeng C., Zhong P., Zhao Y., Kanchana K., Zhang Y., Khan Z.A., et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J Mol Cell Cardiol 2015, 79:1-12.
28. Tauriello D.V., Haegebarth A., Kuper I., Edelmann M.J., Henraat M., Canninga-van Dijk M.R., et al. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 2010, 37:607-619.
29. Jin W., Reiley W.R., Lee A.J., Wright A., Wu X., Zhang M., et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 2007, 282:15884-15893.
30. Hovelmeyer N., Reissig S., Xuan N.T., Adams-Quack P., Lukas D., Nikolaev A., et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 2011, 41:595-601.
31. Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397.
32. Li J., Ichikawa T., Janicki J.S., Cui T. Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets 2009, 13:785-794.
33. Brewer A.C., Murray T.V., Arno M., Zhang M., Anilkumar N.P., Mann G.E., et al. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 2011, 51:205-215.
34. Murray T.V., Smyrnias I., Schnelle M., Mistry R.K., Zhang M., Beretta M., et al. Redox regulation of cardiomyocyte cell cycling via an ERK1/2 and c-Myc-dependent activation of cyclin D2 transcription. J Mol Cell Cardiol 2015, 79:54-68.
35. Wu S., Gao J., Ohlemeyer C., Roos D., Niessen H., Kottgen E., et al. Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med 2005, 39:1601-1610.
36. Wenzel S., Taimor G., Piper H.M., Schluter K.D. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB J. 2001, 15:2291-2293.
37. Sowa M.E., Bennett E.J., Gygi S.P., Harper J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009, 138:389-403.
38. Gao J., Sun L., Huo L., Liu M., Li D., Zhou J. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 2010, 115:4130-4137.
39. Westenbrink B.D., Edwards A.G., McCulloch A.D., Brown J.H. The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. Expert Opin Ther Targets 2013, 17:889-903.
40. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008, 133:978-993.
41. Sawada N., Li Y., Liao J.K. Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol 2010, 10:116-121.